Seeking Alpha
View as an RSS Feed

Tom Genot  

View Tom Genot's Comments BY TICKER:
Latest  |  Highest rated
  • General Electric Rolls On [View article]
    Set it as top 10 picks for 2014.
    Dec 15, 2013. 12:18 AM | 3 Likes Like |Link to Comment
  • GE: Flying High [View article]
    General Electric is gaining in orders from different countries including China, US, and the European continent.
    Dec 13, 2013. 01:57 AM | Likes Like |Link to Comment
  • 3 Stocks That Could Satisfy Your Sweet Tooth For Profits [View article]
    Good job Kapitall. I will give attention to these three,and wish you can keep supplying more analysis...
    Dec 4, 2013. 07:12 AM | 1 Like Like |Link to Comment
  • 4 Reasons Tonix Could Be A Multi-Bagger [View article]
    "Safety

    Safety is a major concern for any drug coming up for approval, but CBP has been approved for decades at doses more than 10 times TNX-102 SL. Add to that the fact that the Phase 2a study had no serious adverse events in the CBP group, and safety is almost a non-issue for TNX-102 SL.

    Sublingual Administration

    TNX-102 SL is faster, more convenient, more effective, has less side effect and compliance risk, and is more suitable for chronic use than oral CBP.

    12 weeks

    TNX-102 SL is well suited for chronic use and the BESTFIT trial is 50% longer than the Phase 2a trial that showed statistical significance in pain versus placebo. An extra month of restful sleep could very well improve symptoms even more.

    Larger sample

    The 2a trial only had 18 patients in each arm, yet was still able to show statistically significant results. With a sample size of more than 3 times the 2a trial, the BESTFIT trial is powered to show statistically significant results even if the results are a little weaker than in the 2a trial. And as we've seen, there are reasons to believe the results will be better than the 2a trial.

    FM selected for special regulatory treatment

    We saw that FM was selected as one of 20 diseases for the FDA to focus on for special regulatory treatment. This is part of the Section X provision in the 2012 PDUFA Reauthorization Performance Goals: Enhancing Benefit-Risk Assessment in Regulatory Decision-Making.

    This provision is designed to assess risk-benefit decisions in diseases where treatment options are not optimal, and to facilitate a program that assesses tolerance for risk on a disease-wide level.

    By naming fibromyalgia a disease to focus on for this program the FDA has acknowledged that FM treatments are lacking and that risk-benefit analysis should play a special role in the review process for FM drugs.

    This bodes very well for TNX-102's approval chances in FM.

    TNX-102 SL meets the sleep quality need in FM and PTSD."

    Yes,totally agree. Excellent article.
    Dec 4, 2013. 07:02 AM | 1 Like Like |Link to Comment
  • Google: Entering New Horizons [View article]
    with the launch of Google Wallet Card, the company is all set to make its presence felt in the online payment market and debit card payment market
    Nov 30, 2013. 09:30 PM | 1 Like Like |Link to Comment
  • Pandora: Momentum Continues As Mobile Monetization Efforts Pay Off [View article]
    Yes,totally agree with you. to the point
    Nov 22, 2013. 09:58 PM | Likes Like |Link to Comment
  • Intel: The Good, The Bad And The Ugly Parts Of Investor Day [View article]
    The stock is trading above 13 times earnings, so it may have more territory to climb as investors seem to have renewed confidence in Intel.
    Nov 22, 2013. 09:54 PM | 2 Likes Like |Link to Comment
  • salesforce.com's CEO Discusses F3Q 2014 Results - Earnings Call Transcript [View article]
    Awesome!
    "salesforce is now the first enterprise cloud computing company to report more than $1 billion in revenue in a single quarter"
    Nov 19, 2013. 04:37 AM | Likes Like |Link to Comment
  • General Electric Is Making The Right Moves [View article]
    Agree with your opinion.
    Nov 19, 2013. 03:24 AM | Likes Like |Link to Comment
  • Reasons To Still Be Long On DVY [View article]
    Thanks for your good analysis...it's useful
    Nov 18, 2013. 02:47 AM | 1 Like Like |Link to Comment
  • Coca-Cola Dividend Raise Coming Soon [View article]
    Can produce what thing all, let our wait and see what happens
    Nov 18, 2013. 02:43 AM | Likes Like |Link to Comment
  • Tesla Is A Hedge Fund's Dream Stock [View article]
    Of course ,30s is still Young Group..:-) and totally agree with your opinion too, a safe car is so important
    Nov 14, 2013. 09:45 AM | 5 Likes Like |Link to Comment
  • Visa Is An Underrated Growth Stock [View article]
    Yes,agree. Deserve special attention .
    Nov 12, 2013. 09:40 PM | Likes Like |Link to Comment
  • Underpriced Intel Reinvents Itself For Mobile [View article]
    Bottom line is that Intel's business is still in a pretty good place and mobile really does represent an attractive growth opportunity
    Nov 12, 2013. 09:36 PM | 1 Like Like |Link to Comment
  • Wall Street Breakfast: Must-Know News [View article]
    "The European Union authorities had said the South Korean company's litigious actions were stifling competition. Samsung faced a potential £11.3bn ($18.3bn) fine if found guilty of breaching European anti-trust laws." BBC News.
    Nov 12, 2013. 07:02 AM | 4 Likes Like |Link to Comment
COMMENTS STATS
18 Comments
19 Likes